Oncomeric Profiles of microRNAs as New Therapeutic Targets for Treatment of Ewing’s Sarcoma: A Composite Review-Reference-Cited by-同舟云学术

Oncomeric Profiles of microRNAs as New Therapeutic Targets for Treatment of Ewing’s Sarcoma: A Composite Review

Published:2023-09-23 Issue:10 Volume:14 Page:1849
ISSN:2073-4425
Container-title:Genes
language:en
Short-container-title:Genes

Author:

Hassan Mubashir¹,Shahzadi Saba¹,Malik Amal²,Din Salah ud³,Yasir Muhammad⁴,Chun Wanjoo⁴^ORCID,Kloczkowski Andrzej¹⁵^ORCID

Affiliation:

1. The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children Hospital, Columbus, OH 43205, USA

2. Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore 54590, Pakistan

3. Department of Bioinformatics, University of Okara, Okara 56130, Pakistan

4. Department of Pharmacology, College of Medicine, Kangwon National University, Chuncheon 24341, Republic of Korea

5. Department of Pediatrics, The Ohio State University, Columbus, OH 43205, USA

Abstract

Ewing’s sarcoma is a rare type of cancer that forms in bones and soft tissues in the body, affecting mostly children and young adults. Current treatments for ES are limited to chemotherapy and/or radiation, followed by surgery. Recently, microRNAs have shown favourable results as latent diagnostic and prognostic biomarkers in various cancers. Furthermore, microRNAs have shown to be a good therapeutic agent due to their involvement in the dysregulation of various molecular pathways linked to tumour progression, invasion, angiogenesis, and metastasis. In this review, comprehensive data mining was employed to explore various microRNAs that might have therapeutic potential as target molecules in the treatment of ES.

Funder

NSF

NIH

Publisher

MDPI AG

Subject

Genetics (clinical),Genetics

Link

https://www.mdpi.com/2073-4425/14/10/1849/pdf

Reference103 articles.

1. Roundhill, E.A., Pantziarka, P., Liddle, D.E., Shaw, L.A., Albadrani, G., and Burchill, S.A. (2023). Exploiting the stemness and chemoresistance transcriptome of Ewing sarcoma to identify candidate therapeutic targets and drug-repurposing candidates. Cancers, 15.

2. Yasir, M., Park, J., Han, E.-T., Park, W.S., Han, J.-H., Kwon, Y.-S., Lee, H.-J., Hassan, M., Kloczkowski, A., and Chun, W. (2023). Exploration of Flavonoids as Lead Compounds against Ewing Sarcoma through Molecular Docking, Pharmacogenomics Analysis, and Molecular Dynamics Simulations. Molecules, 28.

3. Extraskeletal Ewing’s sarcoma of the mediastinum: Case report;Caltavituro;Front. Oncol.,2023

4. Ewing’s sarcoma: Diagnostic, prognostic, and therapeutic implications of molecular abnormalities;Burchill;J. Clin. Pathol.,2003

5. Norcantharidin modulates the miR-30a/Metadherin/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone;Chen;Biomed. Pharmacother.,2018